Strategies & Technologies Driving Drug Discovery to Market
Subscribe to Drug Discovery & Development All
View Sample

FREE Email Newsletter

DDD Update

Daily news and top headlines for drug research professionals

New Lymphoma Therapy May Be More Effective

November 4, 2010 8:06 am | News | Comments

Diffuse large B-cell lymphoma (DLBCL) accounts for approximately 40% of lymphomas among adults. If left untreated, it is fatal. Existing treatments have a cure rate of slightly over 50% but destroy healthy cells along with the cancer cells.


AT & T Setting Up Health Care Division

November 4, 2010 7:49 am | by Peter Svensson | News | Comments

AT&T Inc. is setting up a division to target the health care industry, hoping to have a significant seat at the table when industry adopts electronic medical records, doctor's visits by video-conferencing and wireless gadgets like remote glucose monitors.


TriRima Found Safe in New Study

November 4, 2010 7:38 am | News | Comments

CeNeRx BioPharma, Inc. announced that a new formulation of TriRima, its lead agent for treatment resistant depression, was safe in a study designed to test whether it is free of the food-induced cardiovascular effects associated with conventional MAO inhibitors.


Hybrigenics Finds New Means to Deliver Inecalcitol

November 4, 2010 7:34 am | News | Comments

Hybrigenics, a bio-pharmaceutical group with a focus on research and development of new cancer treatments, has filed a patent application covering new soft gelatin capsules, tablets or drinking solutions optimized for the delivery of high doses of inecalcitol.


Afinitor Reduces Tumor Size

November 4, 2010 7:27 am | News | Comments

A study has found that patients taking Afinitor (everolimus) tablets experienced a decrease in the size of their subependymal giant cell astrocytoma, a benign brain tumor associated with tuberous sclerosis.


Merck Releases Results of Safinamide Study

November 4, 2010 7:19 am | News | Comments

Merck KGaA and its partner Newron Pharmaceuticals S.p.A. announced the top-line results of an 18-month, double-blind, placebo-controlled extension study of a previously completed and reported 6-month Phase 3 study of safinamide.


Athersys Secures Grants for MultiStem Treatment

November 4, 2010 7:12 am | News | Comments

Athersys, Inc. announced that it has secured three Therapeutic Discovery Project grants as part of the Patient Protection and Affordable Care Act of 2010. These grants were awarded related to Athersys' development of MultiStem.


Shire Presents Phase 3 VPRIV Data

November 4, 2010 7:08 am | News | Comments

Shire plc, the global specialty biopharmaceutical company, presented positive new data from a Phase 3 clinical trial designed to evaluate the efficacy of VPRIV compared with imiglucerase in patients with type 1 Gaucher disease.


DARA Finishes DB959 Diabetes Trial

November 4, 2010 7:03 am | News | Comments

DARA BioSciences, Inc. announced that it has successfully completed a Phase 1 clinical study for DB959, its PPAR (peroxisome proliferator activated receptor) delta/gamma agonist, an oral drug in development for the treatment of Type 2 diabetes.


Colony Picking

November 3, 2010 8:21 am | Product Releases | Comments

RapidPick ‘Lite’ is for users who need high speed colony-picking but don't wish to couple the automated plate-handling and picking/re-arraying functions with the RapidPick's immediate pre-pick media filling and immediate post-pick sealing of the growth/daughter plate.


EMCCD Camera

November 3, 2010 8:16 am | Drug Discovery & Development | Product Releases | Comments

Photometrics, a designer and manufacturer of high-performance CCD and EMCCD cameras for the life sciences announced the release of its new high-speed and sensitive Evolve 128 EMCCD camera.


CRA Opens Three New Offices

November 3, 2010 8:11 am | News | Comments

Clinical Research Advantage, Inc., a provider of a range of research services to pharmaceutical companies and clinical research organizations, announced its expansion into the Omaha/Council Bluffs market with the opening of three local area offices.


Pfenex Launches Reagent Division

November 3, 2010 8:07 am | News | Comments

Pfenex Inc. announced the launch of a new business division, Reagent Proteins. Reagent Proteins will enhance the development scientists’ ability to source complex reagent grade proteins at a competitive price.


Bacterial Infection Major Killer During Flu Outbreaks

November 3, 2010 8:01 am | News | Comments

Secondary infections with bacteria such as Streptococcus pneumoniae, which causes pneumonia, were a major cause of death during the 1918 flu pandemic and may be important in modern pandemics as well.


Antibody Locks Up West Nile's Infection Mechanism

November 3, 2010 7:57 am | News | Comments

Researchers have learned the structure that results when an antibody binds to the West Nile virus, neutralizing the virus by locking up its infection mechanism. The information could help scientists develop a vaccine against the mosquito-borne disease.



You may login with either your assigned username or your e-mail address.
The password field is case sensitive.